AIMS/HYPOTHESIS: The purpose of the study was to test prospectively whether healthy individuals with a family history of type 2 diabetes are more susceptible to adverse metabolic effects during experimental overfeeding. METHODS: We studied the effects of 3 and 28 days of overfeeding by 5,200 kJ/day in 41 sedentary individuals with and without a family history of type 2 diabetes (FH+ and FH- respectively). Measures included body weight, fat distribution (computed tomography) and insulin sensitivity (hyperinsulinaemic-euglycaemic clamp). RESULTS: Body weight was increased compared with baseline at 3 and 28 days in both groups (p < 0.001), FH+ individuals having gained significantly more weight than FH- individuals at 28 days (3.4 +/- 1.6 vs 2.2 +/- 1.4 kg, p < 0.05). Fasting serum insulin and C-peptide were increased at 3 and 28 days compared with baseline in both groups, with greater increases in FH+ than in FH- for insulin at +3 and +28 days (p < 0.01) and C-peptide at +28 days (p < 0.05). Fasting glucose also increased at both time points, but without a significant group effect (p = 0.1). Peripheral insulin sensitivity decreased in the whole cohort at +28 days (54.8 +/- 17.7 to 50.3 +/- 15.6 micromol min(-1) [kg fat-free mass](-1), p = 0.03), and insulin sensitivity by HOMA-IR decreased at both time points (p < 0.001) and to a greater extent in FH+ than in FH- (p = 0.008). Liver fat, subcutaneous and visceral fat increased similarly in the two groups (p < 0.001). CONCLUSIONS: Overfeeding induced weight and fat gain, insulin resistance and hepatic fat deposition in healthy individuals. However, individuals with a family history of type 2 diabetes gained more weight and greater insulin resistance by HOMA-IR. The results of this study suggest that healthy individuals with a family history of type 2 diabetes are predisposed to adverse effects of overfeeding. TRIAL REGISTRATION: ClinicalTrials.gov NCT00562393 FUNDING: The study was funded by the National Health and Medical Research Council (NHMRC), Australia (no. #427639).
AIMS/HYPOTHESIS: The purpose of the study was to test prospectively whether healthy individuals with a family history of type 2 diabetes are more susceptible to adverse metabolic effects during experimental overfeeding. METHODS: We studied the effects of 3 and 28 days of overfeeding by 5,200 kJ/day in 41 sedentary individuals with and without a family history of type 2 diabetes (FH+ and FH- respectively). Measures included body weight, fat distribution (computed tomography) and insulin sensitivity (hyperinsulinaemic-euglycaemic clamp). RESULTS: Body weight was increased compared with baseline at 3 and 28 days in both groups (p < 0.001), FH+ individuals having gained significantly more weight than FH- individuals at 28 days (3.4 +/- 1.6 vs 2.2 +/- 1.4 kg, p < 0.05). Fasting serum insulin and C-peptide were increased at 3 and 28 days compared with baseline in both groups, with greater increases in FH+ than in FH- for insulin at +3 and +28 days (p < 0.01) and C-peptide at +28 days (p < 0.05). Fasting glucose also increased at both time points, but without a significant group effect (p = 0.1). Peripheral insulin sensitivity decreased in the whole cohort at +28 days (54.8 +/- 17.7 to 50.3 +/- 15.6 micromol min(-1) [kg fat-free mass](-1), p = 0.03), and insulin sensitivity by HOMA-IR decreased at both time points (p < 0.001) and to a greater extent in FH+ than in FH- (p = 0.008). Liver fat, subcutaneous and visceral fat increased similarly in the two groups (p < 0.001). CONCLUSIONS: Overfeeding induced weight and fat gain, insulin resistance and hepatic fat deposition in healthy individuals. However, individuals with a family history of type 2 diabetes gained more weight and greater insulin resistance by HOMA-IR. The results of this study suggest that healthy individuals with a family history of type 2 diabetes are predisposed to adverse effects of overfeeding. TRIAL REGISTRATION: ClinicalTrials.gov NCT00562393 FUNDING: The study was funded by the National Health and Medical Research Council (NHMRC), Australia (no. #427639).
Authors: S R Smith; L de Jonge; J J Zachwieja; H Roy; T Nguyen; J C Rood; M M Windhauser; G A Bray Journal: Am J Clin Nutr Date: 2000-02 Impact factor: 7.045
Authors: O P Bachmann; D B Dahl; K Brechtel; J Machann; M Haap; T Maier; M Loviscach; M Stumvoll; C D Claussen; F Schick; H U Häring; S Jacob Journal: Diabetes Date: 2001-11 Impact factor: 9.461
Authors: Birgit Nyholm; Michael F Nielsen; Kurt Kristensen; Søren Nielsen; Torben Østergård; Sten B Pedersen; Thomas Christiansen; Bjørn Richelsen; Michael D Jensen; Ole Schmitz Journal: Eur J Endocrinol Date: 2004-02 Impact factor: 6.664
Authors: Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein Journal: Gastroenterology Date: 2009-01-25 Impact factor: 22.682
Authors: Nigel Turner; Krit Hariharan; Jennifer TidAng; Georgia Frangioudakis; Susan M Beale; Lauren E Wright; Xiao Yi Zeng; Simon J Leslie; Jing-Ya Li; Edward W Kraegen; Gregory J Cooney; Ji-Ming Ye Journal: Diabetes Date: 2009-08-31 Impact factor: 9.461
Authors: D J Cuthbertson; T Steele; J P Wilding; J C Halford; J A Harrold; M Hamer; F Karpe Journal: Int J Obes (Lond) Date: 2017-01-12 Impact factor: 5.095
Authors: M Perusina Lanfranca; J K Thompson; F Bednar; C Halbrook; C Lyssiotis; B Levi; T L Frankel Journal: Semin Cancer Biol Date: 2018-09-28 Impact factor: 15.707
Authors: Charmaine S Tam; Alexander Viardot; Karine Clément; Joan Tordjman; Katherine Tonks; Jerry R Greenfield; Lesley V Campbell; Dorit Samocha-Bonet; Leonie K Heilbronn Journal: Diabetes Date: 2010-06-14 Impact factor: 9.461
Authors: Arthur B Jenkins; Marijka Batterham; Dorit Samocha-Bonet; Katherine Tonks; Jerry R Greenfield; Lesley V Campbell Journal: PLoS One Date: 2013-08-07 Impact factor: 3.240
Authors: Dorit Samocha-Bonet; Lesley V Campbell; Trevor A Mori; Kevin D Croft; Jerry R Greenfield; Nigel Turner; Leonie K Heilbronn Journal: PLoS One Date: 2012-05-07 Impact factor: 3.240